AbbVie and Genmab Announce Epcoritamab R-CHOP Cuts Progression Risk by 51% in Newly Diagnosed DLBCL in Phase 3 EPCORE DLBCL-2 Trial
AbbVie and Genmab report that Epcoritamab R-CHOP reduced the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma, in the Phase 3 EPCORE DLBCL-2 trial. The combination remains investigational.
